DarioHealth Corp.

AI-Proprietary Data Driven Platform For Health

July 2026



Forward-Looking Statement

This presentation of DarioHealth Corp. ("Dario", the "Company", "we" and "our") and statements of our management or agents related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. For example, when we discuss our growth potential and return on investment, our expected gross margins and reduced operating expenses, the proposed path to profitability, the potential market opportunity, potential increase in revenue based on multi-condition accounts, and the expected contract value and potential revenues and product offering, we are using forward-looking statements. Words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate," "will," "would," and other similar expressions all denote forward-looking statements within the meaning of the Act.

Readers are cautioned that actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. Factors that could cause or contribute to such differences include, but are not limited to our compliance with regulatory requirements, the impact of current and any future competition, our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise, our ability to manufacture, market and generate sales of our Dario® diabetes management solution, as well as other factors and risks discussed in the Company's filings (including the results of the Company's commercial and regulatory plans for Dario®) with the U.S. Securities and Exchange Commission (the "SEC").

We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, readers are cautioned that any estimates, forecasts or projections contained in this presentation or as may be discussed by our management or agents have been prepared by our management in good faith on a basis believed to be reasonable. However, such estimates, forecasts and projections involve significant elements of subjective judgment and analysis and no representation can be made as to their attainability. No representation or warranty (express or implied) is made or is to be relied upon as a promise or representation as to our future performance. Readers are cautioned that such estimates, forecasts or projections have not been audited and have not been prepared in conformance with generally accepted accounting principles.

This presentation contains market data related to our business and industry, including projections that are based on a number of assumptions. If these assumptions turn out to be incorrect, our actual results may differ materially from the projections based on these assumptions. As a result, the market for our products may not grow at the rates projected by these data, or at all. If the assumptions upon which the projections are based prove to be incorrect, or if the market for our products fails to grow at the rates projected, our results will differ materially from the projections included in this presentation.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Our Purpose

Leveraging 13B+ proprietary data points and AI to create a future where healthy change is effortless and accessible to all.

Dario is the only health-tech company delivering end-to-end multi-condition chronic care solutions from digital engagement to clinical intervention.

A Snapshot of the DarioHealth Opportunity

AI-Powered Proprietary Data Advantage

- Leveraging 13B+ user data points to improve and build out clinical services and support user navigation
- Comprehensive AI implementation across operations driving significant cost reductions and workflow optimization

13B+ Proprietary Patient Data Points

10-15% OpEx Improvements from AI Implementation

Multi-Condition Platform Advantage

- Unique AI-powered multi-condition chronic disease management platform across cardiometabolic (CMB), behavioral (BH), and musculoskeletal (MSK) care
- Unified offering enables personalized care and delivers efficiency and cost savings with Dario's bundled offering for up to 6+ conditions priced at $74 Per Engaged Member Per Month (PEMPM) versus single-condition vendors priced at $70-$79 PEMPM

~70% Of New Wins are Multi-Condition

$74 Bundled Per Engaged Member Per Month Rate

Substantial Addressable Market

- Large addressable market represents a SAM opportunity of ~$250B+[1] and TAM of over $1 B[2] for digital health platform
- Multi-condition architecture enables rapid expansion without requiring fundamental platform rebuilds

$700B CMB

$190B MSK

$102B BH

Expansion into Provider-Backed Care

r

- Announced June 2026: expansion beyond digital engagement into provider-backed care that connects monitoring, AI-driven triage and clinical intervention
- Enables Dario to pursue larger healthcare spend categories including doctor visits, prescription, and diagnostics

4X CMS Access Revenue Potential

$900B+ Medicaid Managed Care Spend

Exceptional Revenue Quality and SaaS-Like Unit Economics

- Transitioning to annual recurring revenue based on high-quality enterprise contracts with Q1 '26 GAAP gross margins of 57% and robust 80%+ non-GAAP gross margins for the 9th consecutive quarter[(2)]
- Multi-year B2B2C / B2B contracts with 90% client retention rates provide high visibility into future revenue potential

80%+ B2B2C Gross Margins Non-GAAP

90% Client Retention

Proven Commercial Strategy & Market Execution

- Strong commercial momentum: $12.9 M in new business contracted and late stage ARR; $127M+ pipeline of commercial opportunities with 70% of them being for multi-condition
- Blue-chip customer base with 160+ clients, including Fortune 100 employers and national health plans

$13M New Annual Recurring Revenues

$127M Pipeline of Commercial Opportunities

Financial and customer metrics are as of March 31, 2026.

dario

Notes: (1) and (2) Refer to sources and links on slide 8. (3) GAAP gross margins in the first quarter of 2026 were 57%; Non-GAAP B2B2C contracts yielded 80%+ gross margins

One Multi-Condition Platform. Powerful Engagement. Proven Outcomes.

One Integrated, Gen-AI-Powered, Human-Enabled, Digital Engagement Platform

Cardiometabolic Health

Diabetes
Pre-Diabetes
Hypertension
Weight Management
GLP-1 Support
Obstructive Sleep Apnea Co-Management
Women's Health

Behavioral Health

Mental Health (Including Maternal MH)
Depression and Anxiety
Stress Management and Resilience

Musculoskeletal Health

Chronic Pain
Joint Pain
Posture Management & ergonomics



A Wealth of Benefits that Engage Members, Drive Real Behavioral Change, and Deliver Timely Clinical Interventions

- Behavioral Change
- Clinical Action and Prescribing
- Community and Education
- Self-Guided Programs
- AI-Powered Human Coaching
- AI Analytics and Data
- Digital Tools
- Connected Devices

Delivering Measurable Clinical Outcomes and ROI

Real-world, third-party-validated clinical studies have proven product excellence and helped quantify the benefits for clients and members

CLINICAL OUTCOMES

Diabetes & Hypertension

13 mmHg Reduction
in systolic blood pressure for over 66% of members with baseline Stage 1 hypertension or higher

1.4–2.3 pt Reduction
in A1C

58% Reduction
in hyperglycemic events

MSK

50% Reduction
in pain* level

76% of members improved
pain* level

Mental Wellbeing

26% Reduction
in depression symptoms

26% Reduction
in anxiety symptoms

ROI

$5,077
medical cost savings for Dario users

100+
published studies, 9 done by Sanofi

9%
population health improvement
well-controlled, 13% poorly controlled

USER EXPERIENCE

App Store Rating

4.8/5
stars

~25,000
reviews

Customer Loyalty

91%
Logo Retention year-over-year

*among members with baseline pain scores .6 on a 0-10 scale

dario

Sources: Management Information; ADA 2022 708-P; AADE 2018; ADA2023 962-P; ADA 2018 77-LB; Frontiers in Physiology 2022; CHASM 2022; ADA 2023 146-LB; ISPOR 2023, and JMIR 2025 by Sanofi

Powerful Market Tailwinds Driving Digital Chronic Care Adoption

Converging cost pressures, treatment innovations, and AI capabilities are driving a rapid shift to integrated digital solutions

90%
of aggregate U.S. healthcare spending accounted for chronic diseases

3 in 4
adults in the U.S. have a chronic disease

5 in 10
adults in the U.S. have two or more chronic diseases

$4.8T
annual health care costs to the U.S. economy

Multi-Condition Care Gap

Digital solutions for multi-condition chronic care showing growth potential but lacking clear market leaders

Cost Pressures Drive Digital Adoption

Rising healthcare costs driving employers and payers toward digital health solutions for cost savings

GLP-1: Beyond Weight Loss

GLP-1 market expanding beyond weight loss into broader chronic care management applications

AI-Driven Transformation

AI technologies enabling unprecedented scalability and personalization across healthcare services

Sources: Statistics stated above are published the CDC (https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html and https://www.cdc.gov/chronic-disease/about/index.html)

Dario's Multi-Condition Digital Platform Addresses $250 Billion Market

75% Adults in the U.S. have a chronic disease

>50% of U.S. adults live with two or more comorbid conditions

$1 Trillion+ TAM

>$250 Billion SAM



(Denotes number of patients)

Sources: CDC (75% and 50% chronic condition incidence, obesity $173 B), hypertension $219B, 120 M people with hypertension); NIH (38M people with diabetes); American Diabetes Association ($307B); Grandview Research ($82 GLP-1); Towards Healthcare ($102B) behavioral health; Cleveland Clinic ($381B market and 127 M people with MSK); SAMHSA (61 M people with behavioral health issues); JP Morgan (13M people on GLP-1s).

Notes: SAM (Serviceable Addressable Market) calculated as $74 per member per month (PMPM) for one or more conditions: diabetes, hypertension, GLP-1, MSK; behavioral health calculated at $1.44 per member per annum (PMPA)

Building the Multi-Condition Platform: 10 Years of Strategic Growth

Dario's early leadership in building a comprehensive, multi-condition platform demonstrates strategic vision realized through disciplined execution ahead of market demand



Notes: (1) GLP-1 Support and Sleep Apnea condition management, Direct Care and Behavioral Health Network capabilities also added via partnerships in 2025

DarioHealth Has Driven the Industry Shift to Multi-Condition Platforms

As an early pioneer of the multi-condition strategy, Dario has transformed customer expectations and buyer preferences – driving industry-wide movement away from costly, fragmented point solutions towards integrated platforms that deliver clinical results, reduce costs and eliminate vendor fatigue

DARIO SOLUTION: Supports member needs across multiple conditions **+** **all on one integrated digital platform**

Percentage of employers with 500+ employees prioritizing these indications





Sources: Data from 2020 / 2021 Mercer National Survey of Employer-Sponsored Health Plans

Today Dario is Leading the Next Big Shift in Healthcare

A category expansion from digital engagement to clinical intervention.

Dario recently announced an expansion into provider-backed care that substantially expands its addressable markets

Before		Dario Now
Monitor	→	Detect
Coach	→	Predict
Engage	→	Treat: Connect with clinician for treatment, prescription, diagnostics

Provider-backed care

National Clinical Infrastructure

- 50-state provider network
- Prescribing capability
- Diagnostic testing
- Escalation from AI to clinician

$1.4 – $2.2B
Integrated Delivery Network TAM

$900B
Medicaid Managed Care Spend

14.3M
ACO Medicare Beneficiaries

Captures a larger share of healthcare spending by connecting AI-driven engagement with provider-backed clinical care.

Dario's Trailblazing Stands Apart

Most competitors excel at one part of the care journey. Dario is integrating the entire journey.

AI & Data → Engagement → Risk Detection → Provider Care → Longitudinal

NEW

Capability	Other Digital Health Solutions	Dario
Address multi-vendor responsibilities	No	✓
Multi-condition gap closure	No	✓
Validated outcomes w/HEDIS & STAR impact	No	✓
Prescription/Rx capability & labs	Limited	✓
Billable under medical benefit	Limited	✓
AI-driven personalization	Limited	✓

Dario is evolving beyond digital health into an AI-driven integrated healthcare platform capable of delivering optimized outcomes for members and higher ROI for payers.

Addressing Healthcare's Most Costly and Prevalent Conditions

Dario's platform targets chronic conditions driving the highest healthcare costs and member prevalence

Diabetes

Hypertension



Pre/Diabetes Weight Management

with GLP-1 Support

Posture Management



Mental Health



CARDIOMETABOLIC ADD ONS

Dario Sleep (OSA)
Home Sleep Test + Sleep Therapeutics/Rx

GLP-1 Rx
Rx, utilization management

Dario Women's Health
Women's Mid-Life Metabolic Health

VIA PARTNERSHIPS

Direct Care

Falls Prevention

Dario Health (Cardiometabolic) | **Dario Move** | **Dario Mind**

Comprehensive Multi-Model Support to Drive Sustained Engagement

Dario's digital-first, human-centered approach combines connected devices, AI-powered coaching, community support, and clinical services to deliver personalized care pathways that maximize member outcomes and ROI

MODES OF ENGAGEMENT

Behavioral Change



- Clinically reviewed interventions
- Evidence-based activities and games

Community and Education



- Clinician-reviewed content
- Access to medical experts
- Peer-to-peer support groups

Self-Guided Programs



- Nutrition tracker
- Medical device guides and tutorials

AI-Powered Human Coaching



- Dedicated human support
- AI digital coaching

Digital Tools

- Medication scanner and management
- Grocery scanner and recipe library
- Health trackers

Connected Devices



- Glucose meter
- Blood pressure monitor
- Connected scale

+

ENHANCED CLINICAL CAPABILITIES

When members require clinical intervention beyond digital-first engagement, Dario's integrated partner network provides seamless access to therapy, prescribing, specialty care, and clinical services – maintaining an asset-light model for delivering comprehensive solutions without building provider infrastructure

dario

The Stack Unique to Dario

Fully Vertically Integrated, from FDA-cleared hardware to proprietary data to Gen AI. We own every layer.

1

FDA-Cleared Connected Devices

Proprietary hardware generating continuous bio-chemical & clinical data. Not rented. Not licensed. Ours.

→

2

13B+ Real-World Data Points

Tied to actual clinical outcomes. Longitudinal. Individual-member level. Across multiple conditions.

→

3

DarioIQ™ AI Engine

Runs on our data. Trained on outcomes no general-purpose model can access or replicate.

→

4

Member Engagement Layer

Behavior-triggered interventions. Personalized. Real-time. Measurable impact today.

Competitors can build an engagement layer, but not Dario's dataset.

The Largest Database of its Kind

Every member added deepens the moat. The dataset that built the advantage is the same one that compounds it.

Member joins, device activates

Real-time clinical data captured

DarioIQ™ learns, personalizes care

Outcomes improve, evidence compounds

New AI models trained & deployed

Payers see ROI, platform expands

13B+

Data Points & Growing

DarioIQ™ - Dario's Proprietary Gen-AI layer is active today

Engine driving engagement and value across the business now

What DarioIQ™ Is Doing Now

Personalizes at the member level, not the segment

Tailors content, timing, and channel to each member's own data signature — only possible because we own the data.

Reaches members at the right moment, automatically

Triggers the right intervention from each member's behavior

Compounds with every member we add

More members generate more data, which makes the engine sharper for everyone.

What It's Producing

Behavior-triggered engagement, now scaling to a broader member population.

40% **Increase in member engagement** vs. control group

20% **Improvement in member retention** vs. control group

Why General AI Models Can't Catch Up

Every advance in AI raises the value of the underlying data. We own that data.

General AI / LLMs	DarioIQ™ on the Dario Platform
✗ Trained on public internet data	✓ **Trained on 13B+ real clinical outcomes**
✗ No longitudinal individual data	✓ **Years of continuous longitudinal member data**
✗ No FDA-cleared device data inputs	✓ **Connected-device stream: biochemical & behavioral**
✗ Generic recommendations	✓ **Personalized to each clinical signature, in real time**
✗ Replicable by any competitor	✓ **Dataset took a decade — cannot be fast-followed**

AI also Across Dario Operations

Active across the company today — automating workflows and compressing cost and cycle time.

AI inside the operating model

Directly resulting in improved operating efficiencies

Workflow Automation

Automating work across product, data, clinical ops, support, and finance

R&D Acceleration

AI across backlog analysis, code generation, testing, and release readiness

Member Engagement

DarioIQ™ personalizes and triggers the right outreach at the right moment

Client Reporting

Faster QBR prep, sharper billing and revenue visibility, quicker client comms

Commercial Overview

How Dario Works for Its Customers and Members

Enrolling & Engaging Members

Total Eligible Population	Drive Enrollment	Create Engagement	Power Personalization	Improve User Outcomes
40%	**35%**	**75%**	**2.4**	**2-5X ROI**
Eligible population across 6+ conditions	Average member activation rate within a customer account	Average member retention rate after 12 months	Average number of Dario solutions a member utilizes	100+ studies highlighting outcomes improved linked to Dario products

$74
Per Engaged Member Per Month
(Full suite)

EXAMPLE

Employer with **10,000 employees** → **1,400** employees enrolled → **$900K** in yearly revenue (post churn)

Source: Management Information

Dario's Competitive Advantage: Multiple Conditions, Better Outcomes, Higher Value

Among the few consumer-centric, multi-condition solutions with real world clinical studies that show tangible results for payers, employers and end users alike



Comprehensive user-centric experience drives higher client win rate and **sustained user engagement**

Sustained engagement leads to **clinical and economic performance (proven by real world data)**

Digital, self-care foundations drive clinical outcomes before driving users to more expensive care modalities, avoiding undesired utilization

Software-based solution allows for a competitive pricing model in comparison to provider-led peers

Growing Blue-Chip Client Base and Channel Partners

Clients

B2B2C
Employer

amazon | Google | Zillow | BAUSCH + LOMB | PRINCETON UNIVERSITY | H&R BLOCK

and 160+

B2B2C
Insurers

CVS Health | aetna | Colorado Access | Sentara | CENTENE Corporation + wellcare

+5

B2B
Pharma

Lilly

+1

Partners

amwell | personify HEALTH | Solera | OneStep | BELUGA HEALTH | Rula | GreenKey Health | Dexcom | Alliant | Rima

High-Conviction Growth Levers Provide Significant Upside Opportunity

Management has identified clear pathways to accelerate growth across existing channels, expand product reach, and improve unit economics

Growth Avenues

Employers |

- Continue to leverage broker/consultants
- Leverage health plans and newly targeted PBMs and TPAs to get into larger employers at a lower cost of sales
- Stay consistent with channel partners that have demonstrated market access to this segment

Health Plans |

- Focus on all lines of business – but keep balance towards commercial, Medicaid (maternal) and Medicare Advantage
- Emphasis on costs of care savings

Channel Partners |

- Continue to work with delivering partners
- Add new focus towards PBMs and TPAs
- Evaluating Pharma channel partnerships

Continue to Improve Engagement/Enrollment

- Improve tech to increase enrollment and engagement rates
- Add claims-based data and analytics

Expand product reach

- Add conditions to increase eligible populations, covered lives
- Improve tech to increase enrollment rates
- Add new condition partners that will allow Dario to gain more market share (MSK, Sleep)

DarioHealth Commercial Evolution

From direct sales to channel-enabled partner leverage

LEGACY SALES FUNNEL: (DIRECT)

High CAC
Expensive direct-to-employer model

Long sales cycle
Extended time-to-close deals

Limited reach
Single condition, constrained scale

Low leverage
One-to-one sales relationships

TODAY: CHANNEL-ENABLED PARTNER NETWORK

DARIO ----> PARTNERS ----> CLIENTS ----> MEMBERS

dario

- Digital Health Platforms
- Third Party Admin.
- Pharmacy Benefits Mgrs
- Benefits Consultants

Employers

Health Plans

Members

✓ Low CAC
✓ One-to-many access
✓ Multi-condition platform
✓ Scalable growth

Dario Uses a Flexible Pricing Model Tailored to Each Commercial Channel

B2B2C

Membership-driven
monthly recurring revenue

Stakeholders per channel:

Health Plans / PBMs

Managed Medicare & Medicaid

Fully insured commercial

Self-Insured Employers

Direct to Employer

Benefit Consultants /Brokers

Through health plans and PBMs

B2C

Membership-driven
monthly recurring revenue

Members

(Users on Dario platform)

Direct to Consumer

Uninsured Individuals

Pricing models:

Per Engaged Member per Month (PEMPM)

- Applied to cardiometabolic and MSK conditions
- Paid per member that is engaged on the platform
- Price is **$74/engaged member/month**

Per Employee per Month (PEPM)

- Behavioral health and mid-market multi-condition customers
- Paid per eligible member that will have access to the platform
- BH price is single digit **between $0.12 and $0.25/employee/month**

Milestone Pricing

- Applied to metabolic conditions and full suite customers
- 5 milestones over 12 months, total milestones = $500 to $1,000+
- Milestones based upon engagement, device usage, clinical outcomes

Source: Management Information

Key Financial Metrics

Financial Snapshot | Q1/2026

$5.6M
Second consecutive quarter of sequential growth
with new ARR B2B2C business model

+7% organic QoQ vs. Q4 2025

57% and 80%
57% GAAP gross margin
80% Non-GAAP gross margin B2B2C business*

9 consecutive quarters

$22.4M
2025 full year revenues

Transitioning to ARR model

-21%
GAAP OpEx reduction YoY vs. Q1 2025
$13.3M → $10.5M in Q1 2026

Lowest since Twill acquisition

-22%
GAAP operating loss improvement YoY vs. Q1 2025
$9.4M → $7.3 M in Q1 2026

-8% Non-GAAP vs Q1 2025

-10%
Decline in net cash used
in operating activities YoY vs. Q1 2025

Path to cashflow breakeven

95 new contracts
85 new signed in 2025 + 10 in Q1 2026
Average contract size 2X-10X ↑ historical

>2x annual target

$127M pipeline
241 opportunities

Primarily B2B2C opportunities

$12.9M ARR
New contracted and late-stage ARR
opportunities, based on management estimates

Contributing to 2026-2027 growth

Q1 ended March 31, 2026
*See Non-GAAP reconciliation table in appendix

Capital Structure

Balance sheet & capitalization snapshot as of March 31, 2026

Stock Price **$8.02**
(as of March 31, 2026)

	Shares Outstanding	Market Cap (as of March 31, 2026)
Common Stock	7,299K	**~$59M**
Pre-Funded Warrants	2,378K	
	9,677K	**~$78M***
Warrants	628K	
Weighted average **$22.52**		
ESOP and RSUs (allocated)	315K	
Outstanding Equity (on a fully diluted basis)	**10,620K**	

- Cash balance and short-term deposits as of March 31, 2026 - $20 million
- Long term debt of $32.5 million

*Assumes full exercise of pre-funded warrants

dario

In Summary

The Time Is Now: Unprecedented Moment for Growth

The groundwork is complete. Internal readiness & external conditions are aligned for accelerated growth

Multi-Condition Platform Leadership

6+
chronic conditions on one platform (vs. 1-3 for most competitors)

70%
of new contracts are multi-condition

70%
of pipeline is multi-condition

Buyers are consolidating vendors for better ROI, savings, and outcomes

+

Expanding Market Access

$127M
Pipeline of commercial opportunities[1]

~116M
lives covered by strong channel partners

These deals are accelerating sales and enabling rapid onboarding of large employers and health plans

+

Transition to Clinical Chronic Care Management

50
State physician network

$1.4-$2.2 B
Integrated Delivery Network TAM

$900B+
Medicaid managed care spend

Unlocking larger share of healthcare spend

Velocity and Multiplier Effect

Validated Multi-Condition Platform + **~116M** Accessible Lives + Owning the Entire Care Journey → **Compounding Momentum for Rapid ARR Expansion and Margin Improvement**

Source: Management Information, ADA 2023 126-LB
Note: (1) As of 3/31/26

Experienced Executive Management Team

Erez Raphael
CEO, Board Member

amdocs

Steven Nelson
President and Chief Commercial Officer

contigohealth | Anthem.

Chen Franco Yehuda
Chief Financial Officer

pluri | pwc | BRENMILLER

Lara Dodo
Chief Operating Officer

mri | Robert Half

Omar Manejwala, M.D.
Chief Medical Officer

catasys

Mona Dean
Chief Compliance Officer

MERCK | J&J

Christopher Strafaci
SVP, Health Plans

SafelyYou | Cogentix

Rob Halpern
SVP, Marketing

pagerhealth | TELADOC.

Matthew Shields
VP, Client Delivery

LetsGetChecked | newtopia | fitbit

Anthony Porretta
VP, Enterprise Sales East

contigohealth | evolent | HIGHMARK.

Chris Harmon
VP, Enterprise Sales West

Quantum Health | Sibly

Members and Clients Love Dario

Tara
Joint and muscle pain

I've reduced my chiro visits from three times a week to just once a month — it's like I've reclaimed my life!

Dylan
Cardiometabolic

For the first time, I feel like I'm in control of my condition instead of just overwhelmed.



Elaina
Anxiety

With Dario I've developed new skills for preventing worry, cultivating relationships, and setting good sleep habits.

Members

Alex
Health plan administrator

Our customers are saving over $5,000 per individual, and they're seeing better outcomes as well.

Benjamin
Broker

We had a great experience with Dario. Implementation was actually a delight!

Michelle
VP of Benefits

We saved money — and our employees love using the device and having access to a coach.

Clients